The Future of Healthcare and Digital Health Solutions in 2026

Healthcare is moving out of the clinic. Monitoring that used to happen twice a year at an appointment now runs continuously, on hardware the patient wears or carries. That turns chronic disease from something you react to into something you catch early, and it is the change people are pointing at when they praise digital health.

If you are deciding what to build or what to buy, the useful question is which parts of it have cleared a regulator and found someone willing to pay, with evidence a health system will accept. The rest are pilots. 

We have spent over a decade shipping healthcare software under HIPAA, FDA and EU MDR, and our healthcare software team has watched where that line falls.

What Makes Digital Health Harder to Build Than Other Software?

Passing clearance proves less than people assume. The pathway most products take shows that a device is equivalent to something already on the market, which says nothing about better patient outcomes. 

The Epic Sepsis Model shows the cost of that gap: deployed widely at 33% sensitivity, it generated roughly seven false alerts for every actionable one. Clinicians stop trusting a tool that behaves that way.

Getting this right takes medicine, software engineering, regulatory affairs, security and design pulling in the same direction. Few organizations have all five in-house on day one, which is why you decide how you staff the build long before it reaches procurement. The comparison below is our own assessment.

All three routes end with you still having to produce the evidence, but they influence how long it takes to get there.

How Does Digital Health Reduce the Cost of Care?

Digital health saves money by shortening the time between something changing in a patient's body and a clinician acting on it. Everything else in the stack serves that.

Start with what the sensors change. A patient with uncontrolled hypertension who is seen twice a year produces two blood pressure readings a year. The same patient on a connected cuff produces several hundred.

That changes what the clinician can do. A medication adjustment that would have waited for the next appointment can happen within days.

That is why remote monitoring programs report hospitalizations avoided. Readmission and bed-day rates are the numbers that move.

Those numbers are also where the money is. A self-insured employer sees it as direct spend. A health system on value-based contracts sees penalty exposure. To a device vendor, it is the evidence that justifies a reimbursement code.

The same logic runs upstream through screening. Catching disease before symptoms turns an expensive late-stage pathway into a cheap early-stage one, and for colorectal cancer, five-year survival is around 90% with early diagnosis against 14% when found late.

What is Driving Demand for Digital Health Solutions?

Three things are driving this market:

• Technology has matured 

• Regulators have cleared more solutions

• Patient expectations have evolved 

Growth is still there, but its shape changed after the pandemic peak.

Money came back in 2026, and it clustered. The first half of the year came in at $6.4 billion across 245 deals a year earlier, and the median deal rose from $12 million in 2025 to $14 million. 

19 companies closed 20 rounds of $100 million or more, taking 45% of all capital deployed, up from 22% in 2024. The median company is raising more than it did last year. 

Still, the headline total is increasingly set by a handful of very large rounds, so a founder benchmarking against it will overestimate what an ordinary round now looks like.

Regulators are not moving evenly across medicine. Radiology accounts for 76% of FDA AI authorizations, cardiovascular for 10% and neurology for 4%. That tells you where predicate devices already exist to point at, and where a submission still has to argue from scratch.

Patients search symptoms before the appointment, book through an app, and increasingly ask a chatbot what a result means. Whatever you build now lands on top of those habits. 

Our roundup of HealthTech trends and the startups behind them tracks which categories that demand is landing in.

Why Should Healthcare Systems Focus on Patients More Than on Institutions?

Too much of what frustrates patients exists because it suits the institution. Appointment slots, referral paths, and access to your own health information are arranged around how a clinic runs rather than around the person walking into it. Physicians are there to serve patients, but the systems around them rarely reflect that.

Access has improved substantially. In 2024, 65% of individuals were offered and accessed their online medical record or patient portal, up from 25% in 2014, and app-based access rose from 38% in 2020 to 57% in 2024.

The problem is that everything is in pieces. Access improved one provider at a time, so anyone who sees several ends up with several separate records and no way to see them together. Consumer platforms are taking on part of that stitching job, which means pulling records into one view is now a platform feature.

When patients reach their own data easily, they become active participants. They can hand a full history to a new provider, follow trends, and make informed decisions. The technology to make healthcare patient-centered exists, but adopting it is a procurement and incentive issue.

How Does Prevention Reduce Healthcare Costs More Than Treatment?

The economics of prevention are well documented.

An investment of $10 per person per year in community-based prevention saves $16 billion annually within five years, a return of $5.60 for every $1 spent. 

Musculoskeletal conditions show it most clearly. A June 2024 Risk Strategies Consulting study of Sword Health participants found $3,177 in annualized savings per member, a 50% reduction in MSK surgeries and 3.2x medical cost ROI.

Remote patient monitoring shows the same clinical effect, with the same caveat. HealthSnap's 2024 outcomes report, a company release covering 41,940 monitored patients, recorded a 23.8 mmHg systolic reduction in Stage 2 hypertension with over 80% of patients improving. A lot of this category's outcome data still comes from the vendors selling into it, which is the argument for funding independent trials.

The reason any of this works for patients is that it asks nothing of them. Monitoring runs in the background while you work or watch television, and it only interrupts when something needs attention. 

The harder problem is on the buying side: prevention pays back over years rather than quarters, so the buyer is usually a self-insured employer or a capitated health system.

How do Mobile Devices and Wearables Enable Digital Health?

We tend to put off doctor's appointments, which can cause us to miss early symptoms of developing conditions. Digital health takes the appointment out of the equation, because it’s in your pocket.

Wearables have stopped competing on how many sensors they pack in and started competing on which claims they are allowed to make. Sleep apnea notification and hypertension alerting have cleared. Sleep scores and recovery metrics are still classed as wellness. Check which side of that line a signal sits on before you design a feature around it, because it determines what you can say about the output.

That leads straight to the build decision. Ship your own hardware, or integrate with someone else's. Integrating gets you to market faster and hands you an installed base. Owning the hardware gives you control over signal quality and over the claim you can make about it. Most teams working on chronic disease integrate first and revisit hardware once the clinical claim holds up.

Either way, consumer hardware now feeds regulated work. We built Convatec's iOS application to collect Apple Watch heart rate variability data for clinical trials, which is a consumer sensor feeding a medical device correlation study. Whether what you build counts as a medical device turns on what you intend it to do.

Why is Real-time Health Data Changing Clinical Decisions?

You go to the clinic and have an examination. You wait seven working days for the results, then another three to see the physician who reads them. Over those ten days, your condition can worsen or resolve, meaning the treatment eventually prescribed may be wrong or no longer needed.

Sensors close that gap, and continuous glucose monitoring is the clearest example. The first over-the-counter CGM cleared on 5 March 2024, for adults who do not use insulin, changed who a product has to go through to reach someone: no prescriber required. ECG on consumer wearables is the more familiar case, though it works differently: it gives you a reading you have to ask for.

More devices are clearing than are proving themselves, and buyers have started asking about the difference. The BASEL Wearable Study found Apple Watch 6 and Samsung Galaxy Watch 3 each hitting 85% sensitivity and 75% specificity for atrial fibrillation detection. Good enough to screen with. Not good enough to diagnose on.

Look at the wider literature, and the weakness is in how the studies were designed. A 2024 scoping review of 80 studies on wearables for remote monitoring found only six were randomized controlled trials, and four of those six showed positive clinical impact. Running a proper trial is the expensive part, and it is the easiest thing to push out of a first budget.

Why Does Centralized Health Data Lead to Better Care?

Every clinic collects a great deal about every patient and keeps it in a system that doesn't talk to others. Specialists end up working from partial records, treating the piece in front of them.

US policy has closed part of that gap. USCDI version 3 became the nationwide interoperability standard, carrying 94 data elements across 19 classes, including for equity and public health. Eleven organizations now operate as Designated Qualified Health Information Networks under TEFCA, and CommonWell alone connects 37,000 provider organizations nationwide.

One vendor's share now shapes every integration decision you make. Epic's acute care EHR market share reached 42.3% in 2024, up from 39.1% a year earlier, according to KLAS figures. If your product cannot write into an Epic workflow, you are asking clinicians to leave the system they live in all day to use it. Budget for that integration at the start.

Pulling data together concentrates the risk along with the value. 289 million individuals were affected by health data breaches in 2024 across 779 large incidents, with the Change Healthcare attack accounting for 192.7 million on its own. Security architecture is something you decide in the first sprint.

What Environmental and Lifestyle Factors Affect Your Health?

Your clinical state is only part of the picture. Your ZIP code, your genes, your family, how connected you are, what you eat and how much you move all shift the outcome. Patients who trust their clinician do measurably better than those seen by someone rushed or unfriendly.

There is less and less time in an appointment to ask about any of it. Decades ago, most of a visit covered history, circumstances and how the patient felt, with a small share for tests. That ratio has flipped as time per patient has been squeezed, and the gap it left is what digital tools are filling.

Genetic risk screening reached consumers first, and the platforms followed. Health records, medication reminders and food logging now live inside the same apps people already open for their steps and their sleep.

Mental health is where all of this context meets actual clinical care, and it comes with a warning that matters commercially. Many mental health applications lack clinical regulation, and their creators often lack clinical training. Build here and expect the line between wellness support and clinical treatment to be examined closely, both by regulators and by the health systems you want to sell to. 

We built Spoke, a music-therapy platform for young adults' mental health, with that boundary in view from the first design session.

How Are Digital Health Leaders Shaping the Industry?

The big platforms have split into two camps. One sells sensors with regulatory claims attached, and the other sells the infrastructure everyone else builds on.

Leaders That Sell Sensors

Apple is firmly in this first camp. Its watches carry cleared sleep apnea notifications, derived from accelerometer-based breathing analysis, and hypertension alerts built on optical heart-sensor trends. 

Its continuing study with Johnson & Johnson investigates whether early atrial fibrillation detection reduces stroke risk, a condition that is frequently asymptomatic until it causes a stroke.

Google is running both a consumer line and a research line. Fitbit Labs tests conversational features against personal health data, while AlphaFold won Demis Hassabis and John Jumper a share of the 2024 Nobel Prize in Chemistry for predicting protein structure. Amazon took a different route, folding its telehealth service into One Medical and putting pharmacy kiosks inside clinics.

Leaders That Sell Infrastructure

Microsoft and NVIDIA sell to builders rather than patients, supplying medical imaging models, compliant agent tooling, and most of the infrastructure healthcare AI gets trained on. 

The model developers followed: OpenAI built HealthBench with 262 physicians from 60 countries, and Anthropic launched Claude for Life Sciences for literature review and regulatory submission drafting. We have written separately on where large language models fit clinical workflows.

If you are building, the takeaway is that both the sensing layer and the model layer have become commodities. What is left to compete on is the clinical claim you can defend and the workflow you can get into.

What Makes a Successful Digital Health Application?

Four things separate products that reach revenue from those that clear review and then stall.

Picking the right problem comes first, because all the regulatory and clinical work only pays for itself if the problem underneath is real. Validate that before you write production code.

Security is a decision you make once, at the beginning. Health data needs encryption at rest and in transit, multi-factor authentication and regular penetration testing, designed in. Our guide to testing and QA for health applications covers how that gets verified.

Your regulatory strategy decides your architecture, and 2026 rewrote the European half of it. 

The first four EUDAMED modules became mandatory on 28 May 2026, covering actor registration, device registration, notified bodies and market surveillance. The AI Act then lays a second set of obligations over the same devices. Most of it applies from 2 August 2026, with high-risk classification following on 2 August 2027, and a device in class IIa or above is in practice classified as high-risk by default. In the US, HIPAA safeguards and an FDA submission pathway run in parallel, and a predetermined change control plan is what lets you retrain a model without filing all over again. 

Even apps that never called themselves medical devices have drawn FTC enforcement over how they shared user data with advertisers. Hence, the exposure reaches well past products holding a clearance letter.

User experience is the fourth, and the one budgets reach last. Retention is what builds the long-run dataset everything commercial depends on later, so the design decisions that look cosmetic at kickoff are the ones that decide whether you can run an outcome study at all.

How Do You Choose the Right Partner for Digital Health Development?

Choosing a partner here comes down far more to regulatory capability than day rate. Here is what to look for, and what a weak answer sounds like.

Find a partner who clears all five, and all you need to bring is the clinical insight and your commitment. They take on the technical complexity, the regulatory navigation and the design. 

Our Vave Health engagement is what that looks like with real constraints attached: a React Native rebuild for a wireless ultrasound device holding FDA clearance, covering both the device communication protocol and the clinical interface. The product has run more than 1 million scanning sessions.

Have the budget conversation before scoping, because compliance, validation and integration are what drive the number. 

Our breakdown of healthcare app development costs covers how each moves the figure, and our review of the top healthcare software development companies of 2026 compares vendors across the region.

What Does the Future Hold for Digital Health?

Ambient documentation is an AI category where the evidence has reached the scale of whole health systems. A JAMA Network Open study published on 2 October 2025, covering 263 clinicians across six health systems, found burnout fell from 51.9% to 38.8% after 30 days of ambient scribe use, along with lower cognitive load and less after-hours documentation. What it gives back is clinician time, which is the scarcest resource in any health system.

How care gets delivered moved next. After the original waiver lapsed in late 2025, Congress extended hospital-at-home through 2030 in the Consolidated Appropriations Act, 2026, with 366 programs across 139 health systems and 37 states approved at the time. Five years of certainty removes the annual reauthorization scramble that has kept health systems from investing capital in permanent infrastructure. That is what turns the model from an experiment into something you can finance.

What clinical AI can do is run ahead of anyone's plan for deploying it safely. Dr. Eric Topol points to screening and age-related disease as the strongest applications, with detection before physical signs appear the clearest near-term gain, and has noted that AI systems working independently sometimes outperform the same systems combined with physician input. Governance is what is lagging, with unsanctioned AI use spreading faster than the policies meant to cover it.

What Do You Need to Build a Digital Health Product?

Four conditions decide whether a digital health product reaches revenue.

Classification

A wellness tool and a regulated medical device carry different documentation burdens and release processes, and the choice is not one you can't revisit once the build is underway. 

It also governs how you ship: you cannot casually patch a validated system, which is what the change control plan above relieves. 

European products carry MDR conformity assessment today, with AI Act obligations arriving on the timetable set out earlier, and GDPR shapes your hosting before the first deployment.

Reimbursement

Somebody has to pay for the intervention your data triggers. 

Where a reimbursement code exists, you are selling into a budget that is already there. Where it does not, your buyer is a self-insured employer or a capitated system paying out of its own avoided costs, which is a slower sale. 

Either way, your cost per patient has to sit under what that buyer saves or is paid, or the program dies of its own success.

Evidence

Clearance will not substitute for evidence. 

The literature above is thin for a reason: a proper study is expensive, and it has to be planned while the product is still being built. 

Retrofitting a trial onto a shipped product usually means shipping it twice.

Clinician Adoption

Epic's installed share makes writing into an Epic workflow a market-access requirement, with FHIR conformance if you want the exchange networks. 

Past that, alert fatigue kills adoption faster than any missing feature, and post-market surveillance needs documentation that outlives the engagement. 

Our post on technical debt in HealthTech covers what deferring these decisions costs later.

Does Digital Health Investment Pay Off?

The products that work here shorten the gap between a signal from the body and a clinical response, then prove it in outcome data a payer will accept. Sensors, models and interfaces all exist to serve that, and the convergence of AI, genomics, wearables and remote monitoring is what makes a more predictive system reachable.

What has changed since the funding peak is that the constraints are now readable. 

Regulatory pathways are defined, EUDAMED and the AI Act carry fixed dates, hospital-at-home is funded through the decade, and EHR consolidation makes integration requirements predictable. The uncertainty has moved from the rules to the evidence, which is the better problem to have, because evidence is something you can plan and budget for.

In practice, that means designing the clinical validation study alongside the product, and settling the compliance architecture in the first sprint. Teams that get that order right reach the evidence stage while they still have runway. If you are scoping a product against these constraints, our healthcare product development team works through pathway, integration surface and evidence strategy before the first line of production code.